AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by stock analysts at Janney Montgomery Scott in a research note issued to investors on Tuesday.

A number of other equities research analysts have also commented on the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, October 4th. Cantor Fitzgerald reissued a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Morgan Stanley assumed coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They set an “overweight” rating and a $26.00 target price for the company. Deutsche Bank AG reaffirmed a “hold” rating and set a $24.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Finally, BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $27.67.

AMAG Pharmaceuticals (NASDAQ AMAG) opened at 16.25 on Tuesday. AMAG Pharmaceuticals has a one year low of $16.00 and a one year high of $36.83. The firm’s market capitalization is $573.43 million. The company’s 50-day moving average is $18.44 and its 200-day moving average is $19.11.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. AMAG Pharmaceuticals’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.45 EPS. Equities analysts forecast that AMAG Pharmaceuticals will post ($1.38) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Rating Reiterated by Janney Montgomery Scott” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/19/amag-pharmaceuticals-inc-amag-rating-reiterated-by-janney-montgomery-scott.html.

A number of institutional investors and hedge funds have recently made changes to their positions in AMAG. First Trust Advisors LP increased its holdings in AMAG Pharmaceuticals by 49.5% in the 1st quarter. First Trust Advisors LP now owns 55,055 shares of the specialty pharmaceutical company’s stock worth $1,241,000 after acquiring an additional 18,227 shares during the last quarter. Comerica Bank increased its holdings in AMAG Pharmaceuticals by 4.5% in the 1st quarter. Comerica Bank now owns 38,047 shares of the specialty pharmaceutical company’s stock worth $936,000 after acquiring an additional 1,648 shares during the last quarter. Karp Capital Management Corp purchased a new stake in AMAG Pharmaceuticals in the 1st quarter worth about $232,000. Sei Investments Co. increased its holdings in AMAG Pharmaceuticals by 0.7% in the 1st quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after acquiring an additional 54 shares during the last quarter. Finally, Mason Street Advisors LLC increased its holdings in AMAG Pharmaceuticals by 7.4% in the 1st quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after acquiring an additional 554 shares during the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.